Technology | Contrast Media | December 11, 2017

Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software

Radiologists can now collect, store and monitor contrast injection data during MRI exams

Sectra Offers Gadolinium Tracking Functionality in DoseTrack Software

December 11, 2017 — Sectra recently announced the global introduction of gadolinium tracking in its dose monitoring solution, Sectra DoseTrack. Gadolinium is a contrast agent commonly used to enhance images during magnetic resonance imaging (MRI) exams. By systematically registering gadolinium information, healthcare providers can reduce the risk of patients experiencing negative side effects of excessively high accumulated levels of gadolinium.

Sectra showcased Sectra DoseTrack, including this functionality, during the Radiological Society of North America (RSNA) annual meeting, Nov. 26-Dec. 1, 2017 in Chicago.

Ian Judd, product manager for Sectra DoseTrack, said by entering gadolinium injection information in the software, healthcare providers can ensure relevant information is available throughout the organization either from the electronic medical record (EMR), from the dose monitoring solution or in Sectra PACS (picture archiving and communication system).

Sectra DoseTrack allows healthcare providers to monitor patient radiation exposure and ensure that the radiation doses are kept as low as reasonably achievable (ALARA) for increased patient safety. The cloud-based solution automatically collects, stores and monitors data from all connected modalities, saving time and facilitating robust analysis for dose optimization. It can be configured using local and national dose reference levels (DRLs) to allow healthcare organizations to ensure it is performing within expected thresholds.

Watch the VIDEO How Serious is MRI Gadolinium Retention in the Brain and Body?

Read the article FDA: No Harm in MRI Gadolinium Retention in the Brain

For more information: www.sectra.com

 

Related Content

FDA Clears Mirada Medical's Simplicit90y Dosimetry Software
News | Interventional Radiology | February 18, 2019
February 18, 2019 — Mirada Medical Ltd announced U.S.
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
Veterans Integrated Service Network 19 Implements System-Wide Radiation Dose Monitoring
News | Radiation Dose Management | December 04, 2018
Agfa HealthCare announced it has collaborated in delivering a system-wide DoseMonitor automated software implementation...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...